This asset has been in my watchlist for a while, with a lot of good entries on it for a long term bullish scenario. Here we can see a lot of confluence on this level for a potential long entry. We have multiples support from different timeframe (daily one and 4h one too), the fibonacci retracement level perfect bounce (needs to hold it now) and a liquidity...
Here is a spot I have been waiting for since the $16.0 rejection level (big absorption of the buyers on the top). Same mecanique as my EUR/USD swing position previously with a smooth spot at $10.0 psychological and technical level of interest. First breakdown of the level with then a new high as high as the previous one (little bit higher) for then a retest of the...
Dublin-headquartered biopharmaceutical company Avadel Pharmaceuticals currently has a buzzy formulation of sodium oxybate in a Phase 3 clinical trial for the treatment of narcolepsy, among other candidates. The current twice-nightly U.S. narcolepsy oxybate market is estimated at $1.8 billion -- up to half of those patients quit because they need to wake up in the...
Looks like a push to the 618 fib retracement might be up next. If we have an impulsive 5 up incoming the chart should look like this IMO.
Avadel Pharmaceuticals is a biotech company which is currently anticipating approval for FT218, a drug treating narcolepsy. Im not gonna go in depth on it cuz it really doesn’t matter for the swing I'm tryna do, but basically breakthrough therapies like FT218 are highly demanded by investors. Thus, when it breaks out of this multi-year consolidation zone (the...
Description: AVDL is trending higher and in an uptrend meaning that highs are getting higher and lows are getting higher. The uptrend line on the chart and the Trending Band Indicator (which measures trend) supports the Long Position. Stats: 1. Ideal buy range: $8 - $8.4 2. Take profit: $10.01 3. Stop Loss: $7.7 4. Risk To Reward: 1 / 5 5. Accuracy Rating: 96%
Contextual immersion trading strategy idea. Avadel Pharmaceuticals operates as a specialty pharmaceutical company in the United States, France, and Ireland. The demand for shares of the company looks lower than the supply. This and other conditions can cause a fall in the share price in the next days. So I opened a short position from $5,23; stop-loss —...
AVDL: Avadel Pharmaceuticals plc 2020-04-27 07:00:10 Avadel Pharmaceuticals Announces Positive Topline Results from its Pivotal Phase 3 REST-ON Trial of Once-Nightly FT218 for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy
ON watch-list for sustained rally Bullish reversal on indicators
For the past year we can see that the market was not taking any price above 3.59. It mostly stayed between a range of 1.7 to 3.59. But recently the chart broke out on 9/19-9/23 and then started to fall back to its original range. the next couple weeks show promising strong movement. If it falls back into its yearly range it will stay there with 3.59 being its...
Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. It offers Bloxiverz, Vazculep, and Akovaz. The company was founded on December 1, 2015 and is headquartered in Dublin, Ireland. SHORT INTEREST 6.53M 07/31/19 P/E Current -0.85 P/E Ratio (with extraordinary items) -0.80 Average Recommendation: BUY Average...
AVDL possible reverse head and shoulders - on watch for this
*******STRONG BREAKOUT COMING**** Avadel Pharmaceuticals plc (AVDL), today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for the Company’s fourth Hospital Product, AV001. It has been granted Priority Review status by the FDA resulting in a six-month review period. The FDA has assigned a Prescription Drug...